Skip to main content

Table 2 Treatment-emergent adverse events with a ≥ 5% frequency of occurrence in either galcanezumab dose group

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Event Galcanezumab 120 mg
N = 129
n (%)
Galcanezumab 240 mg
N = 141
n (%)
Patient with ≥1 TEAE 106 (82.2) 121 (85.8)
Injection site pain 22 (17.1) 28 (19.9)
Nasopharyngitis 23 (17.8) 18 (12.8)
Upper respiratory tract infection 9 (7.0) 21 (14.9)
Injection site reaction 15 (11.6) 13 (9.2)
Back pain 12 (9.3) 15 (10.6)
Sinusitis 14 (10.9) 13 (9.2)
Nausea 10 (7.8) 9 (6.4)
Injections site erythema 9 (7.0) 9 (6.4)
Arthralgia 8 (6.2) 8 (5.7)
Influenza 8 (6.2) 8 (5.7)
Dizziness 5 (3.9) 9 (6.4)
Injection site bruising 5 (3.9) 8 (5.7)
Myalgia 8 (6.2) 3 (2.1)
Weight increased 7 (5.4) 4 (2.8)
  1. TEAE treatment-emergent adverse events
  2. There were no statistically significant differences between dose groups in frequency of events
\